Citigroup Inc. Buys Shares of 42,619 LifeMD, Inc. (NASDAQ:LFMD)

Citigroup Inc. bought a new position in LifeMD, Inc. (NASDAQ:LFMD) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 42,619 shares of the company’s stock, valued at approximately $266,000. Citigroup Inc. owned 0.11% of LifeMD as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the business. State Street Corp boosted its position in LifeMD by 8.2% during the 1st quarter. State Street Corp now owns 72,594 shares of the company’s stock worth $256,000 after acquiring an additional 5,471 shares during the period. Jane Street Group LLC purchased a new position in LifeMD during the second quarter valued at approximately $25,000. Bank of New York Mellon Corp acquired a new position in LifeMD in the 3rd quarter valued at approximately $64,000. Geode Capital Management LLC lifted its position in LifeMD by 4.0% in the 4th quarter. Geode Capital Management LLC now owns 198,867 shares of the company’s stock worth $385,000 after buying an additional 7,723 shares in the last quarter. Finally, Millennium Management LLC acquired a new stake in shares of LifeMD during the 4th quarter valued at $106,000. Hedge funds and other institutional investors own 35.52% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. B. Riley reiterated a “buy” rating on shares of LifeMD in a report on Friday, December 1st. Craig Hallum initiated coverage on LifeMD in a report on Thursday, November 30th. They set a “buy” rating and a $10.00 price target for the company. HC Wainwright boosted their price target on LifeMD from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Thursday, January 11th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $9.00 price objective on shares of LifeMD in a research report on Thursday, December 14th. Finally, BTIG Research boosted their target price on shares of LifeMD from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Friday, March 15th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $10.20.

LifeMD Stock Down 8.0 %

Shares of LFMD stock opened at $10.18 on Thursday. The stock’s 50 day simple moving average is $7.59 and its 200 day simple moving average is $7.02. LifeMD, Inc. has a twelve month low of $1.40 and a twelve month high of $12.01. The company has a debt-to-equity ratio of 3.22, a quick ratio of 1.15 and a current ratio of 1.22. The company has a market capitalization of $410.97 million, a price-to-earnings ratio of -14.54 and a beta of 1.41.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.